Pharma business news, market intelligence, and CEO-level case studies.
Oral PCSK9 Inhibitor Approved: LIPFENDRA Price vs Repatha Witfire Elite Cardiometabolic Pricing & Access Market Case Studies Long Read Pharma Market Case Studies Witfire Elite View Oral PCSK9… ...
Oral PCSK9 Inhibitor Approved: LIPFENDRA Price vs Repatha Witfire Elite Cardiometabolic Pricing & Access Market Case Studies Long Read Pharma Market Case Studies Witfire Elite View Oral PCSK9… ...
Oral PCSK9 Inhibitor Approved: LIPFENDRA Price vs Repatha Witfire Elite Cardiometabolic Pricing & Access Market Case Studies Long Read Pharma Market Case Studies Witfire Elite View Oral PCSK9… ...
Oral PCSK9 Inhibitor Approved: LIPFENDRA Price vs Repatha Witfire Elite Cardiometabolic Pricing & Access Market Case Studies Long Read Pharma Market Case Studies Witfire Elite View Oral PCSK9… ...
Bright biotech illustration for Unicycive’s OLC CRL, showing nanoparticle formulation, manufacturing control strategy, FDA quality risk and CDMO execution failure. The FDA did not reject Oxylanthanum ...
4SigHT is formally a long-term observational study. Strategically, its timing points to something larger: Tanabe is building a Japanese real-world evidence moat before Bristol Myers Squibb brings a ...
Viridian’s Lumvoa approval is not only a new thyroid eye disease launch. It is the first real crack in Amgen’s Tepezza-controlled market. The label is broad, the course is shorter, and the diplopia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results